• Molecular NameGalantamine
  • Synonym(-)-Galanthamine; Galanthamine; Galanthamine hydrobromide
  • Weight287.359
  • Drugbank_IDDB00674
  • ACS_NO357-70-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.16
  • pka8.2
  • LogD (pH=7, predicted)-0.72
  • Solubility (experiment)10 mg/ml (HBr salt)
  • LogS (predicted, ACD/Labs)(ph=7)-0.87
  • LogSw (predicted, AB/LogsW2.0)2.06
  • Sw (mg/ml) (predicted, ACD/Labs)4.21
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA41.93
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA chemical used for the treatment of mild to moderate Alzheimer’s disease and various memory impairments.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding18.0
  • Volume of distribution (VD)2.64 L/kg (194.8 L)
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmGalantamine is metabolised in the liver by the cytochrome P450 isoenzymes, CYP2D6 and CYP3A4, and approx. 75% of the dose is metabolised. Metabolites include norgalantamine (active), N-oxide-galantamine, O-desmethylgalantamine (active), O-desmethylnorgalantamine (active), epigalantamine and galantaminone. No active metabolites have been detected in the unconjugated forms in plasma.
  • Half life5.7 h
  • ExcretionThe majority of the dose is excreted in urine; 18 to 22% as the unchanged drug during the 24 h period after dosing. A minor amount is excreted in faeces. The drug does not appear to accumulate after multiple dosing.
  • Urinary Excretion20
  • Clerance5.7 ml/min/kg
  • ToxicitySignificant overdosing of galantamine can lead to signs and symptoms similar to those observed with overdosing of other cholinomimetics; generally involving the central nervous system, the parasympathetic nervous system and the neuromuscular junction. Symptoms include muscle weakness or fasciculations, severe nausea, vomiting, gastro-intestinal cramping, salivation, lacrimation, urination, defecation, sweating, bradycardia, hypotension, collapse and convulsions. Increasing muscle weakness along with tracheal hypersecretions and bronchospasm, may result in vital airway compromise. [Patient information leaflet, Janssen-Cilag Ltd.]
  • LD50 (rat)LD50=75 mg/kg
  • LD50 (mouse)LD50=10 (ip)